Regeneron Shares Tumble Premarket After Fianlimab Study Failure
RSS SUMMARY · AGGREGATED FROM TWSJ
The stock fell sharply after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
The stock fell sharply after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
The stock fell sharply after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
World News
The Hormuz Squeeze Is Redrawing the Oil Map for Good
TWSJ·5m ago·3 min read
Tech
Meta Keeps Delaying the Release of Its New AI Model to Developers
TWSJ·15m ago·3 min read
World News
Russia’s Elite Is Souring on the War. Putin Doesn’t Seem to Care.
TWSJ·1h ago·3 min read
Tech
Top AI CEOs Call for Law Protecting Against Biological Weapons
TWSJ·2h ago·3 min read
Related
On this beat
Health
An Uncertain Path for Americans Exposed to Ebola
TNYT·7h ago·3 min read
Health
Autism therapy has attracted predatory providers who bill for phantom services, pad hours and charge steep fees for care delivered by low-paid workers. Here are five takeaways from a WSJ investigation
TWSJ·11h ago·3 min read
Health
New research could help doctors tweak anesthesia to more resemble natural sleep, reducing risks
TWSJ·11h ago·3 min read
Health
Diets high in ultraprocessed foods are associated with an increased risk of dementia, a new study says, adding to the list of health problems linked to foods such as cookies, hot dogs and pizza
TWSJ·18h ago·3 min read